| 1. |
Guidelines for the initial use of low molecular weight heparins (LMWHs) in acute-care hospitals have been developed |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 426,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
Biological agents cost effective in the treatment of RA |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 426,
2003,
Page 3-4
L Hunt,
Preview
|
|
摘要:
Biological agents have been shown to reduce the symptoms of rheumatoid arthritis (RA) when used in clinical trials. These agents have also demonstrated their ability to retard joint damage and improve physical function, leading to better health-related QOL. Currently, there are a number of biological agents available in the US to treat RA, including adalimumab, anakinra, etanercept and infliximab. Researchers from the US evaluated the costs and outcomes associated with biological agents used to treat RA, and found that etanercept was the most cost-effective treatment option, whether used as monotherapy or in combination with methotrexate.1The results were presented at the Annual European Congress of Rheumatology [Lisbon, Portugal; June 2003]. A second study presented at the meeting revealed that, compared with infliximab, etanercept was more effective and less costly in the treatment of RA,2while a multinational investigative team showed that, in patients who were partially responsive to methotrexate, potential lifetime treatment with infliximab was cost effective in Portuguese patients with RA.3All three studies received financial support from Wyeth.
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
Enfuvirtide, valdecoxib endorsed by Scottish Medicines Consortium |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 426,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Vancomycin use suboptimal in hospitalised paediatrics |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 426,
2003,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
The level of reimbursement is the most influential factor in restricting physicians' use of serotonin receptor antagonists |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 426,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Warfarin prescribing in nonvalvular atrial fibrillation is strongly influenced by the perceived risks of warfarin use, |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 426,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
Resource use high with influenza, RSV infections |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 426,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
Insulin aspart improves treatment satisfaction, QOL vs human insulin |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 426,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
Omeprazole OTC brandname change requested, second generic version launched |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 426,
2003,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Global drug sales up by 7% |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 426,
2003,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
